BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28837575)

  • 1. Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    Seebacher V; Aust S; D'Andrea D; Grimm C; Reiser E; Tiringer D; Von Mersi H; Polterauer S; Reinthaller A; Helmy-Bader S
    PLoS One; 2017; 12(8):e0182383. PubMed ID: 28837575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.
    Vanderstichele A; Busschaert P; Smeets D; Landolfo C; Van Nieuwenhuysen E; Leunen K; Neven P; Amant F; Mahner S; Braicu EI; Zeilinger R; Coosemans A; Timmerman D; Lambrechts D; Vergote I
    Clin Cancer Res; 2017 May; 23(9):2223-2231. PubMed ID: 27852697
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Urban RR; Pappas TC; Bullock RG; Munroe DG; Bonato V; Agnew K; Goff BA
    Gynecol Oncol; 2018 Aug; 150(2):318-323. PubMed ID: 29929922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.
    Coleman RL; Herzog TJ; Chan DW; Munroe DG; Pappas TC; Smith A; Zhang Z; Wolf J
    Am J Obstet Gynecol; 2016 Jul; 215(1):82.e1-82.e11. PubMed ID: 26970494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram based on the O-RADS for predicting the malignancy risk of adnexal masses with complex ultrasound morphology.
    Gong LP; Li XY; Wu YN; Dong S; Zhang S; Feng YN; Lv YE; Guo XJ; Peng YQ; Du XS; Tian JW; Sun CX; Sun LT
    J Ovarian Res; 2023 Mar; 16(1):57. PubMed ID: 36945000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Guo Y; Jiang T; Ouyang L; Li X; He W; Zhang Z; Shen H; You Z; Yang G; Lai H
    Gynecol Oncol; 2021 Mar; 160(3):704-712. PubMed ID: 33357959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
    Hefler-Frischmuth K; Lafleur J; Hefler L; Polterauer S; Seebacher V; Reinthaller A; Grimm C
    Gynecol Oncol; 2015 Mar; 136(3):567-70. PubMed ID: 25576886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group.
    Timmerman D; Van Calster B; Testa AC; Guerriero S; Fischerova D; Lissoni AA; Van Holsbeke C; Fruscio R; Czekierdowski A; Jurkovic D; Savelli L; Vergote I; Bourne T; Van Huffel S; Valentin L
    Ultrasound Obstet Gynecol; 2010 Aug; 36(2):226-34. PubMed ID: 20455203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis.
    Wynants L; Timmerman D; Verbakel JY; Testa A; Savelli L; Fischerova D; Franchi D; Van Holsbeke C; Epstein E; Froyman W; Guerriero S; Rossi A; Fruscio R; Leone FP; Bourne T; Valentin L; Van Calster B
    Clin Cancer Res; 2017 Sep; 23(17):5082-5090. PubMed ID: 28512173
    [No Abstract]   [Full Text] [Related]  

  • 10. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
    Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Preoperative Scoring System for Adnexal Mass in Children and Adolescents to Preserve Their Future Fertility.
    Depoers C; Martin FA; Nyangoh Timoh K; Morcet J; Proisy M; Henno S; Lavoue V; Arnaud AP
    J Pediatr Adolesc Gynecol; 2019 Feb; 32(1):57-63. PubMed ID: 30205159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
    Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
    Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-Stage Ovarian Malignancy Score versus Risk of Malignancy Indices: Accuracy and Clinical Utility for Preoperative Diagnosis of Women with Adnexal Masses.
    Phinyo P; Patumanond J; Saenrungmuaeng P; Chirdchim W; Pipanmekaporn T; Tantraworasin A; Tongsong T; Tantipalakorn C
    Medicina (Kaunas); 2020 Dec; 56(12):. PubMed ID: 33339091
    [No Abstract]   [Full Text] [Related]  

  • 14. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
    Timmerman D; Van Calster B; Jurkovic D; Valentin L; Testa AC; Bernard JP; Van Holsbeke C; Van Huffel S; Vergote I; Bourne T
    J Clin Oncol; 2007 Sep; 25(27):4194-200. PubMed ID: 17698805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
    Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
    Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study.
    Van Holsbeke C; Van Calster B; Testa AC; Domali E; Lu C; Van Huffel S; Valentin L; Timmerman D
    Clin Cancer Res; 2009 Jan; 15(2):684-91. PubMed ID: 19147775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
    Worasethsin P; Narkwichean A
    J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help.
    Valentin L; Ameye L; Savelli L; Fruscio R; Leone FP; Czekierdowski A; Lissoni AA; Fischerova D; Guerriero S; Van Holsbeke C; Van Huffel S; Timmerman D
    Ultrasound Obstet Gynecol; 2011 Oct; 38(4):456-65. PubMed ID: 21520475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.